The effect of the HMG-CoA reductase inhibitor simvastatin and of cholestyramine on hepatic apolipoprotein mRNA levels in the rat
A Mitchell, N Fidge, P Griffiths - Biochimica et Biophysica Acta (BBA)-Lipids …, 1993 - Elsevier
We have administered the hypolipaemic drugs simvastatin and cholestyramine to rats, both
separately and together, to determine whether drug-induced changes in plasma apo
lipoprotein levels occur through regulation of hepatic genes coding for apolipoproteins
(apos) AI, AIV, E and B. Cholestyramine alone had little effect on either the plasma levels of
the apolipoproteins studied or their hepatic mRNA levels. However, simvastatin, either alone
or in combination with cholestyramine, produced marked changes in both of these …
separately and together, to determine whether drug-induced changes in plasma apo
lipoprotein levels occur through regulation of hepatic genes coding for apolipoproteins
(apos) AI, AIV, E and B. Cholestyramine alone had little effect on either the plasma levels of
the apolipoproteins studied or their hepatic mRNA levels. However, simvastatin, either alone
or in combination with cholestyramine, produced marked changes in both of these …